TRF2 is in neuroglial cytoplasm and induces neurite-like processes

Yusun Junga, Seungku Leea, Seunghyun Banga, Soonok Kimb, Kyungho Choi, Changhee Leea, Seong-Gene Leea, Chong Jai Kimb, Kyuyoung Songc, Inchul Leed,*

aAsan Institute for Life Sciences, University of Ulsan College of Medicine, 388-1 Poongnap-dong, Songpa-Gu, Seoul 138-736, South Korea
bDepartment of Pathology, Seoul National University College of Medicine, 28 Yongon-dong, Chongno-gu, Seoul 110-799, South Korea
cDepartment of Biochemistry, University of Ulsan College of Medicine, 388-1 Poongnap-dong, Songpa-Gu, Seoul 138-736, South Korea
dDepartment of Pathology, University of Ulsan College of Medicine, 388-4 Poongnap-dong, Songpa-Gu, Seoul 138-736, South Korea

Received 9 October 2003; accepted 7 December 2003
First published online 18 December 2003

Edited by Horst Feldmann

Abstract TRF2 is a ubiquitous protein that protects telomeres in the nucleus. We found that TRF2 was present at the peripheral nerve axons and the brain neuroglial cell processes extensively. It was in the cytoplasmic membrane as well as nuclear fractions, but not in the soluble cytoplasmic fraction of SH-SY5Y neuroblastoma cells. TRF2 was up-regulated in P19 embryonal carcinoma cells at the early stage of induced neuronal differentiation with retinoic acid treatment. Upon transfection, TRF2-expressing COS cells often produced neurite-like processes. TRF2 is a component of neuroglial cells and appears to be involved in the cytoplasmic process formation that is necessary for neural differentiation.

© 2003 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.

Key words: TRF2; Neural differentiation; Glia; Axon; Neurite

1. Introduction

TRF2 (TTAGGG repeat binding factor 2) is a nuclear protein that coats the length of all human telomeres at all stages of the cell cycle [1,2]. It protects telomeres from end-to-end fusion [3] by forming large duplex loops at the end [4]. It delays replicative senescence of cultured cells by protecting critically short telomeres from fusion [5].

TRF2 inhibition leads to immediate induction of apoptosis suggesting that TRF2-depleted telomeres are perceived as if they represent sites of DNA damage [6]. TRF2 binds with several telomere-regulating proteins such as hRap1 [7]. Mre11 complex [8], Ku [9], and Werner and Bloom syndrome helicases [10], suggesting that it protects and maintains the telomere function in collaboration with other proteins. The down-regulation of TRF2 has been implicated in malignancies [11,12].

We have screened the expression of TRF2 in various tissues using affinity-purified anti-TRF2 antibody [9]. Upon immunohistochemical staining, we unexpectedly found that TRF2 was present not only in the nuclei but also at the axon of peripheral nerves and brain tissue. Here, we show that TRF2 is a neuroglial cell component and induces neurite-like cytoplasmic process formation. Our results suggest that TRF2 has a novel function of neurite formation that is not related to the telomere-protecting function.

2. Materials and methods

2.1. Immunochemistry

Paraffin-embedded and/or fresh human tissue samples from various organs were obtained from autopsy and surgical pathology files at Asan Medical Center, Seoul, Korea, with informed written consent. For the immunohistochemical staining, sections of 4 µm thickness were prepared from paraffin blocks. Microwave antigen retrieval was applied in 0.01 M sodium citrate buffer (pH 6.0). The affinity-purified anti-TRF2 antibody was produced against recombinant TRF2 expressed in Esherichia coli [9]. For negative control, antigen pre-absorbed antibody was applied. Anti-TuJ1 (Covance, Richmond, CA, USA), anti-neuN (Chemicon, Temecula, CA, USA), anti-neuN (Chemicon, Temecula, CA, USA), anti-synaptophysin (DakoCytomation, Carpinteria, CA, USA), and anti-neurofilament (DakoCytomation) antibodies were applied for 2 h at room temperature similarly. After washing, immunostaining was done using the avidin-biotinylated horseradish peroxidase complex method, and was developed by immersing slides in diaminobenzidine as chromogen.

2.2. Tissue culture and induced neural differentiation

SH-SY5Y [13] and COS cells were grown at 37°C (5% CO2) in Dulbecco’s modified Eagle’s medium (Invitrogen, Carlsbad, CA, USA) supplemented with 10% (v/v) fetal bovine serum, penicillin (100 IU/ml), and streptomycin (100 mg/ml). P19 cells obtained from the American Type Culture Collection (Rockville, MD, USA) [14] were cultured in α-minimal essential medium (Invitrogen) supplemented with 7.5% fetal bovine serum and 2.5% fetal calf serum (Invitrogen). To induce neuronal differentiation, SH-SY5Y cells were incubated in complete medium plus 1 µM all-trans retinoic acid (Sigma, St. Louis, MO, USA) for 5 days [15].
P19 cells were grown in 100 mm bacteriological grade Petri dishes. To induce neuronal differentiation, all-trans retinoic acid was added to the medium to a final concentration of 0.5 µM [16]. After 4 days, the cell aggregates were trypsinized, transferred into tissue culture dishes and cultured for an additional 5 days in the same medium without retinoic acid. Cells were harvested every 24 h and analyzed by Western blot for 5 days.

2.3. Cell fractionation

Cell fractionation experiments were repeated twice independently. SH-SY5Y cells were washed with cold phosphate-buffered saline (PBS), scraped from the plates and allowed to swell in 0.5 ml of lysis buffer (50 mM Tris–HCl (pH 7.4), 2 mM EDTA, 2 mM EGTA, 1 mM dithiothreitol, 10 µg/ml leupeptin, 10 µg/ml aprotanin, 10 µg/ml trypsin inhibitor, 1 mM phenylmethylsulfonyl fluoride, 1 mM NaF, 1 mM sodium orthovanadate, 0.1% (w/v) Triton X-100) on ice for 10 min. Then, cells were homogenized with 10 gentle strokes of a glass-to-glass Dounce homogenizer. The homogenates were first centrifuged at 600×g and 4°C for 20 min) to obtain a crude nuclear pellet and a soluble fraction. The purity of the nuclear preparations was moni-
To understand the TRF2 function further, we surveyed the expression in human tissues by immunohistochemistry using affinity-purified rabbit antisera [9]. In every organ, most cells were immunostained in the nuclei, although the staining intensity varied considerably. Unexpectedly, we found that peripheral nerve axons were strongly immunostained regardless of the size or location (Fig. 1A). Similarly, the brain was also extensively immunostained while antigen pre-absorbed control antibodies did not show any staining. All neurons had intense TRF2 immunostaining throughout the soma and processes displaying the complex neural network of the brain (Fig. 1B). There was also a finely fibrillar staining in the white matter, where no neuron expressing synaptophysin was present, indicating that TRF2 was also present in the glial processes (Fig. 1C,D). The distribution of TRF2 in the central nervous system was reminiscent of TuJ1 (neuron-specific class III β-tubulin) [17] except that nuclei were negative on TuJ1 immunostaining (Fig. 1E). NeuN was expressed in the neuronal nuclei and soma similarly [18], but it was not expressed in glial cells (Fig. 1F). Neuroblastomas and gliomas, which are malignant neural and glial tumors, also strongly expressed TRF2 at the neural and glial processes, respectively (Fig. 1G,H).

As reported previously, TRF2 was detected as two bands of 65 and 69 kDa upon Western blotting [1,2]. The expression of TRF2 varied considerably in different organs: it was much higher in the brain than in organs such as thymus, kidney, lung and liver (Fig. 2A). β-Actin, which was taken as a control, was also highly expressed in the brain. From the densitometric analysis of immunoblots, the TRF2 expression normalized against β-actin in fold increase of control.

3. Results and discussion

3.1. TRF2 is present at the peripheral nerve axons and brain neuroglial cell processes

To understand the TRF2 function further, we surveyed the expression in human tissues by immunohistochemistry using affinity-purified rabbit antisera [9]. In every organ, most cells were immunostained in the nuclei, although the staining intensity varied considerably. Unexpectedly, we found that peripheral nerve axons were strongly immunostained regardless of the size or location (Fig. 1A). Similarly, the brain was also extensively immunostained while antigen pre-absorbed control antibodies did not show any staining. All neurons had intense TRF2 immunostaining throughout the soma and processes displaying the complex neural network of the brain (Fig. 1B). There was also a finely fibrillar staining in the white matter, where no neuron expressing synaptophysin was present, indicating that TRF2 was also present in the glial processes (Fig. 1C,D). The distribution of TRF2 in the central nervous system was reminiscent of TuJ1 (neuron-specific class III β-tubulin) [17] except that nuclei were negative on TuJ1 immunostaining (Fig. 1E). NeuN was expressed in the neuronal nuclei and soma similarly [18], but it was not expressed in glial cells (Fig. 1F). Neuroblastomas and gliomas, which are malignant neural and glial tumors, also strongly expressed TRF2 at the neural and glial processes, respectively (Fig. 1G,H).

As reported previously, TRF2 was detected as two bands of 65 and 69 kDa upon Western blotting [1,2]. The expression of TRF2 varied considerably in different organs: it was much higher in the brain than in organs such as thymus, kidney, lung and liver (Fig. 2A). β-Actin, which was taken as a control, was also highly expressed in the brain. From the densitometric analysis of immunoblots, the TRF2 expression normalized against β-actin was still higher in the brain than in other organs (Fig. 2B).

3.2. TRF2 is in the nuclear and cytoplasmic membrane fractions but not in the soluble cytoplasmic fraction of neuroblastoma cells

We then analyzed in which cellular fraction TRF2 was present. SH-SY5Y neuroblastoma cells were treated with
1 μM retinoic acid to induce neural differentiation [15]. Cells were harvested after 5 days when more than 90% of cells showed TuJ1-positive neurites, and cellular fractions were prepared as described in Section 2. Upon 10% polyacrylamide gel electrophoresis and immunoblotting, TRF2 was detected in the cytoplasmic membrane fraction as well as in the soluble and insoluble nuclear fractions, but not in the soluble cytoplasmic fraction (Fig. 3). TRF2 consisted of two bands with similar proportions in each fraction. From the densitometric analysis, it was estimated that the amount of TRF2 in the cytoplasmic membrane fraction was about 45% of the total TRF2 in the differentiated SH-SY5Y cells.

3.3. TRF2 is up-regulated at the early stage of induced neural differentiation of P19 cells

The abundance of TRF2 in the cytoplasmic membrane fraction suggested a particular function in the nervous system, distinct from the telomere regulation. We checked the expression of TRF2 during the experimental neural differentiation. For the experiment, we used P19 embryonal carcinoma cells instead of SH-SY5Y cells, because the former did not show any visible ‘leakage’ of neurite formation in the culture conditions without retinoic acid. After the exposure to 0.5 μM retinoic acid for 4 days, P19 cells were replated in tissue culture flasks. On immunoblotting, TuJ1 began to be detected 48 h post treatment and increased exponentially afterwards, indicating the induction and ongoing neural differentiation (Fig. 4A, B). TRF2 also increased after the retinoic acid treatment, but in a distinct pattern from TuJ1: the TRF2 expression normalized against β-actin increased up to 2.19 times of the basal level on the third day, and began to decrease afterwards (Fig. 4A,C). The expression of β-actin did not change significantly for 5 days. The TRF2 up-regulation before TuJ1 induction suggested that TRF2 might have a direct role in the induction of neurites at the early stage of neural differentiation.

Fig. 2. Western blot for TRF2 in human tissues. A: Upon loading of 30 μg of total proteins in each lane, the TRF2 expression is much higher in the brain than in other tissues. The control β-actin is also highly expressed in the brain. B: From the densitometric analysis of immunoblots, the TRF2 expression normalized against β-actin was still higher in the brain than in other organs.

Fig. 3. TRF2 is present in the nuclear and cytoplasmic membrane fractions but not in the cytoplasmic soluble fraction of neuroblastoma cells. SH-SY5Y cells were induced to undergo neural differentiation using 1 μM retinoic acid, and cellular fractions were prepared as described. TRF2 was detected as two bands of 65 and 69 kDa with similar proportions among the fractions. Total protein 20 μg was loaded in each lane: 1, soluble nuclear fraction; 2, insoluble nuclear fraction; 3, soluble cytoplasmic fraction; and 4, cytoplasmic membrane fraction.

Fig. 4. TRF2 up-regulation at the early stage of induced neural differentiation. A: Immunoblot using anti-TuJ1, TRF2, and β-actin antibodies. P19 embryonal carcinoma cells were treated with 0.5 μM retinoic acid and harvested every 24 h. Lane 1: untreated control, lanes 2–6: days 1–5 after treatment. Total protein 20 μg was loaded in each lane. B: The expression of TuJ1 normalized against β-actin expression as a control. C: The normalized expression of TRF2.
3.4. TRF2 transfection induces neurite-like processes in COS cells

We then examined whether TRF2 could induce neurite-like processes in cultured cells. COS cells were transfected with either pcDNA3-TRF2/T7-Tag or pcDNA3-TRF2ΔNLM/T7-Tag, a mutant deleted in the N-terminus and the myb-like C-terminus [9]. For negative control, cells were transfected with the vector alone. At 36 h post transfection, cells were processed for immunofluorescence microscopy using anti-TRF2 and/or anti-T7 antibodies. The transfection efficiency varied from 3 to 10% among three repetitions. Transfected COS cells showed strong immunostaining in the nuclei and/or cytoplasm. Among the TRF2-transfected COS cells, about 10–20% had slender cytoplasmic processes, which were not present in the mock transfection. They had two or more processes that were up to 20–30 times of the nuclear length (Fig. 5A,B): the nuclei were small and slender in comparison with other cells. Transfected cells had either bipolar or multipolar processes. The processes were quite reminiscent of neurites: they often showed a beaded appearance, branched and connected to adjacent cell processes. However, they did not express neural markers such as TuJ1, NeuN, neurofilament, or synaptophysin on double immunostaining (data not shown). The neurite-like processes were found on both full-length TRF2 and TRF2ΔNLM transfection, indicating that neither the N- nor the C-terminus was involved in the neurite-like process formation.

Taken together, TRF2 is present abundantly in the cytoplasmic membrane fraction of neural cells, and appears to induce the neurite-like cytoplasmic processes. Our data suggest that the neurite formation may precede further biochemical steps toward mature neurons. The molecular mechanisms of neural process initiation and growth have not been well elucidated. It has been shown that Rho-GTPases and Cdc42 are involved in the axon initiation and growth [19], and the regulation of actin polymerization through the Arp2/3 complex [20]. Given that TRF2 induces neurite-like processes in non-neural cells, it is likely that TRF2 functions upstream of those pathways in the complex molecular mechanism of neural differentiation.

Acknowledgements: We appreciate Drs. Sang-Hun Lee and Sang-Ho Lee for valuable discussions on the neural differentiation of cultured cells. This study was supported by a grant of the Korea Health 21 R&D Project, Ministry of Health and Welfare, Republic of Korea (00-PJ1-PG3-20800-0038).

References